All In Biotech

Drug Trial Radar · NCT00542386

A Study of MCI-196 in Chronic Kidney Disease Subjects on Dialysis With Hyperphosphatemia and Dyslipidaemia

A Phase III, Multi-centre, Double-blind, Randomised, Placebo-controlled Multiple Fixed-dose Study of MCI-196 Versus Placebo in Chronic Kidney Disease Stage V Subjects on Dialysis With Hyperphosphatemia and Dyslipidaemia (Incorporating Two Parallel High Dose Groups)

Last checked: Nov 20, 2026Latest source record: Jan 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 642 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

642

Actual

Start

Dec 2007

Primary completion

Nov 2009

Study completion Nov 2009

Sponsor

Lead sponsor
Tanabe Pharma CorporationIndustry
Sponsor type
Industry
First posted
Oct 11, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase III multi-centre study in two periods: the first period is a phosphate binder and lipid lowering drugs washout for 8 weeks, the second period is a double-blind, randomised, parallel group, fixed dose, for 12 weeks.

Conditions

  • Chronic Kidney Disease
  • Dialysis
  • Hyperphosphatemia
  • Dyslipidemia

Interventions

  • MCI-196Drug

    3g to 15g/day (3 times a day), Tablet, 12 weeks of fixed dose of study

  • PlaceboDrug

    3g to 15g/day (3 times a day), Tablet, 12 weeks of fixed dose of study

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The Change in Serum PhosphorusTime frame: 12 weeks
  2. The Change in LDL-cholesterolTime frame: 12 weeks

Locations

73 sites in 8 countries. Site status is shown where the registry gives one.

  • Site not named

    Ajka, Hungary

  • Site not named

    Baja, Hungary

  • Site not named

    Budapest, Hungary

  • Site not named

    Esztergom, Hungary

  • Site not named

    Győr, Hungary

  • Site not named

    Hatvan, Hungary

  • Site not named

    Kisvárda, Hungary

  • Site not named

    Lecco, Italy

  • Site not named

    Modena, Italy

  • Site not named

    Pavia, Italy

  • Site not named

    Roma, Italy

  • Site not named

    Alor Star, Malaysia

  • Site not named

    Ipoh, Malaysia

  • Site not named

    Kajang, Malaysia

  • Site not named

    Klang, Malaysia

  • Site not named

    Kota Kinabalu, Malaysia

  • Site not named

    Kuala Terengganu, Malaysia

  • Site not named

    Kuantan, Malaysia

  • Site not named

    Kuching, Malaysia

  • Site not named

    Malacca, Malaysia

  • Site not named

    Seremban, Malaysia

  • Site not named

    Taiping, Malaysia

  • Site not named

    Skopje, North Macedonia

  • Site not named

    Lodz, Poland

  • Site not named

    Płock, Poland

  • Site not named

    Poznan, Poland

  • Site not named

    Rybnik, Poland

  • Site not named

    Warsaw, Poland

  • Site not named

    Wroclaw, Poland

  • Site not named

    Zielona Góra, Poland

  • Site not named

    Arkhangelsk, Russia

  • Site not named

    Armavir, Russia

  • Site not named

    Chelyabinsk, Russia

  • Site not named

    Chita, Russia

  • Site not named

    Irkutsk, Russia

  • Site not named

    Ivanovo, Russia

  • Site not named

    Kaluga, Russia

  • Site not named

    Kemerovo, Russia

  • Site not named

    Khabarovsk, Russia

  • Site not named

    Krasnodar, Russia

Showing 40 of 73 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.